Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Brown University
With
Describe the safety of maintenance dasatinib, 100 mg/day for 2 years, in patients with stage III NSCLC. For patients with potentially resectable disease, to assess the pathologic complete response following neoadjuvant dasatinib, paclitaxel, carboplatin and 50.4 Gy concurrent radiation. For patients with locally unresectable disease, to obtain radiographic response data following dasatinib, paclitaxel, carboplatin and 64.8 Gy radiation.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted